![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Mobidiag’s Molecular Test Gains CE Mark
Mobidiag’s Molecular Test Gains CE Mark
![](https://www.fdanews.com/ext/resources/test/Device_Images6/MobiDiag_logo.png?t=1546993236&width=430)
January 8, 2019
Finnish diagnostics developer Mobidiag earned the CE Mark for its Novodiag CarbaR+ test, which can detect bacteria that are resistant to carbapenem antibiotics.
The multiplex qPCR- and microarray-based test detects carbapenemase-producing enterobacteriaceae and provides results in 80 minutes through the company’s automated Novodiag system.
Mobidiag also has two other CE-marked antibiotic resistance screening tests, CarbaR+VRE and CarbaR+MCR, that are run on its Amplidiag multiplex system.
Upcoming Events
-
21Oct